Eosinophilic Granulomatosis Treatment Market - Global Industry Analysis 2014 - 2018 and Forecast 2019 - 2029


Eosinophilic Granulomatosis Treatment  Market
  • To Be Published : Sep-2020 |
  • Status : Work in progress |
  • Format : Eosinophilic Granulomatosis Treatment  Market Eosinophilic Granulomatosis Treatment  Market Eosinophilic Granulomatosis Treatment  Market Eosinophilic Granulomatosis Treatment  Market

Eosinophilic granulomatosis is a rare condition of autoimmune disorder which is generally characterized by acute asthma, inflammation of blood vessels and high level of eosinophills. Eosinophilic granulomatosis is commonly known as Churg-Strauss syndrome. Eosinophilic granulomatosis affects various organs such as lungs, skin, gastrointestinal tract, heart and nervous system. There are three phases of eosinophilic granulomatosis namely as allergic, eosinophilic and vasculitic. Eosinophilic granulomatosis starts with the development of allergy and asthma. In December 2017, FDA approved the first drug therapy for the eosinophilic granulomatosis treatment named as mepolizumab. Market players are trying to expand the therapeutic application of eosinophilic granulomatosis treatment thus creating more opportunity and scope for the growth of the eosinophilic granulomatosis treatment market in the future.

Increasing prevalence of the eosinophilic granulomatosis every year is one of the major factor expected to drive the growth of the eosinophilic granulomatosis treatment market. the increasing demand for new and improved eosinophilic granulomatosis medication is further expected to boost the growth of the eosinophilic granulomatosis treatment market. The increasing research and development activities to expand the therapeutic application of the eosinophilic granulomatosis medication is expected to aid in the growth of the eosinophilic granulomatosis treatment market. Growing awareness of people for early detection and treatment of eosinophilic granulomatosis is supporting the growth of the eosinophilic granulomatosis market. Moreover decreased cost of the eosinophilic granulomatosis drugs is expected to propel the growth of the eosinophilic granulomatosis treatment market. Also, initiatives taken by government to provide early treatment is further pooling the eosinophilic granulomatosis treatment market. Also, new drugs launches and product in pipelines are anticipated to drive the growth of the eosinophilic granulomatosis market. However, least availability of the eosinophilic granulomatosis drugs and several side-effects associated with drug are the major restraints expected to hamper the growth of the eosinophilic granulomatosis treatment market.

The global eosinophilic granulomatosis treatment market is segmented based on the drug class, route of administration, distribution channel and region.

Based on drug class, the global eosinophilic granulomatosis treatment market is segmented as:

  • Mepolizumab
  • Rituximab
  • Benralizumab
  • Omalizumab
  • Methotrexate Sodium
  • Others

Based on route of administration, the global eosinophilic granulomatosis treatment market is segmented as:

  • Oral
  • Intravenous
  • Intramuscular

Based on distribution channel, the global eosinophilic granulomatosis treatment market is segmented as:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

The eosinophilic granulomatosis treatment market is expected to experience robust growth over the forecast period due to increasing diagnosis and cases of eosinophilic granulomatosis affected patients. Among drug class, mepolizumab is expected to hold the major market share in the eosinophilic granulomatosis treatment market. Among route of administration segment, oral route of administration segment is expected to be the most revenue generating segment in eosinophilic granulomatosis treatment market. Among distribution channel segment, retail pharmacies is accounted for significant market share in global eosinophilic granulomatosis treatment market owing to higher patient footfall.

The eosinophilic granulomatosis treatment market is expected to be dominated by the North America due to higher cases of eosinophilic granulomatosis and presence of market players in the region. Also, intensive research and development activities and FDA approval of eosinophilic granulomatosis treatment drugs are further aiding in the growth of the eosinophilic granulomatosis treatment market. Europe is expected to be the second prominent region in the global eosinophilic granulomatosis treatment market owing to the improved healthcare facility and reimbursement policies. Asia-Pacific is expected to be the fastest growing eosinophilic granulomatosis treatment market due to large population residing in countries such as India and China. The higher disposable income of the people and increasing healthcare per capita is also contributing to the eosinophilic granulomatosis treatment market growth. Latin America is expected to witness the steady growth in the near future whereas MEA expected to be the least lucrative growth due to lower adoption in the eosinophilic granulomatosis treatment market.

The key participants operating in the global eosinophilic granulomatosis treatment market are: GlaxoSmithKline LLC, Baxter Healthcare Corporation, Genentech Inc. (F. Hoffmann-La Roche AG), Cephalon Inc. (Teva Pharmaceutical Industries Ltd.), Koninklijke DSM N.V, AstraZeneca plc, Novartis International AG, and Pharmaceuticals Holdings Corp.

The report covers exhaustive analysis on:

  • Eosinophilic granulomatosis treatment Market Segments
  • Eosinophilic granulomatosis treatment Market Dynamics
  • Historical Actual Market Size, 2013 - 2017
  • Eosinophilic granulomatosis treatment Market Size & Forecast 2018 to 2024
  • Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Market Drivers and Restraints 

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size recent industry trends
  • Key Competition landscape
  • Strategies for key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Eosinophilic Granulomatosis Treatment Market

Back To Top